Genetic associations of bradykinin type 2 receptor, alpha-adrenoceptors and endothelial nitric oxide synthase with blood pressure and left ventricular mass in outpatients without overt heart disease

Rafael Amorim Belo Nunes*, Larissa Barbosa Lima, Nelson Ithiro Tanaka, Alexandre da Costa Pereira, José Eduardo Krieger, Alfredo José Mansur

Heart Institute (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil

A R T I C L E   I N F O

Article history:
Received 8 May 2018
Received in revised form 20 August 2018
Accepted 11 September 2018
Available online 2 October 2018

Keywords:
Genetics
Polymorphisms
Left ventricular mass
Blood pressure
Alpha-adrenergic receptors
Bradykinin B2-receptors
Endothelial nitric oxide synthase

A B S T R A C T

Background: Physiological pathways such as bradykinin, renin-angiotensin, neurohormones and nitric oxide have been shown to play an important role in the regulation of cardiovascular function. Genetic variants of these pathways may impact blood pressure and left ventricular (LV) mass in different populations. To evaluate associations of genetic polymorphisms of bradykinin B2 receptor (BDKRB2), alpha-adrenergic receptors (ADRA) and endothelial nitric oxide synthase (eNOS) on the modulation of the blood pressure and the left ventricular mass.

Methods: We enrolled 758 individuals without overt heart disease. Blood pressure was estimated by auscultatory method during the clinical examination. Left ventricular (LV) mass was assessed by echocardiography. Genotypes for ADRA1A rs1048101, ADRA2A rs553668, ADRA2B rs28365031, eNOS rs2070744, eNOS rs1799983, and BDKRB2 rs5810761 polymorphisms were assessed by high-resolution melting analysis.

Results: BDKRB2 polymorphism rs5810761 was associated with blood pressure. Carriers of DD genotype had higher levels of SBP and DBP than carrier of II genotype (p = 0.013 and p = 0.007, respectively). eNOS polymorphism rs1799983 was associated with DBP. Carriers of GT genotype had lower levels of DBP than carriers of GG genotype (p = 0.018). eNOS polymorphism rs2070744 was associated with LV mass. Carriers of TC genotype had higher LV mass than carriers of TT genotype (p = 0.028).

Conclusions: In a cohort of individuals without overt heart disease, the BDKRB2 rs5810761 polymorphism (DD genotype carriers) were associated with higher systolic and diastolic blood pressures, and the eNOS rs1799983 polymorphism (C allele carriers) were associated with lower diastolic blood pressure. The eNOS rs2070744 polymorphism (C allele carriers) was associated with higher left ventricular mass. These data suggest that eNOS and bradykinin receptor genetic variants may be potential markers of common cardiovascular phenotypes.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Blood pressure and left ventricular mass are phenotypes that may be affected by abnormalities of the cardiovascular system such as hypertension, atherosclerosis, endothelial dysfunction, among others. Both are complex traits mediated by intricate interactions between genetic and environmental factors.

Physiological pathways such as bradykinin, renin-angiotensin, neurohormones and nitric oxide have been shown to play an important role in the regulation of cardiovascular function [1]. Genetic variants of these pathways may influence the subclinical phase of common cardiovascular diseases and genetic differences in the regulation of blood pressure and left ventricular mass may be early markers of subclinical development of cardiovascular disorders in apparently healthy individuals.

Previous studies have suggested associations of genetic variants related to these physiological pathways with blood pressure and left ventricular mass. In relation to left ventricular mass, most studies were conducted in patients with hypertension and evaluated principally genes of renin-angiotensin-aldosterone system. A pivotal study conducted by Schunkert and colleagues demonstrated in a population-based sample of 711 women and 717 men that homozygosity for a deletion polymorphism of the angiotensin-converting-enzyme gene was significantly associated with higher odds for left ventricular hypertrophy (LVH) [2]. In other study with 175 Chinese hypertensive patients,
a missense variant of angiotensinogen gene at codon 235 (M235T) predicted an increase in left ventricular mass index in subjects with TT genotype [3].

Other works have also shown a possible association between left ventricular mass and genetic variants of bradykinin receptor type 2 (BDKRB2) gene. In 90 Swedish patients with hypertension, the BDKRB2 +9/+9 genotype was associated with lower regression of LVH in response to antihypertensive treatment [4]. In a Japanese cohort of 275 hypertensive and 441 normotensive subjects, in which a BDKRB2 gene polymorphism (587C/T) and an insertion/deletion variant of angiotensin converting enzyme (ACE) gene were genotyped, the prevalence of LVH in patients with hypertension was higher in those with both the BDKRB2 CC and ACE D allele than those with other genotypes [5]. Additionally, genetic variants related to endothelial nitric oxide were also studied regarding the left ventricular mass. In a study with 600 hypertensive patients and 600 healthy controls, a Glu298Asp variant of the endothelial nitric oxide synthase (eNOS) gene was not tied to hypertension, left ventricular mass and carotid artery intima-media thickness [6]. In another study with 127 parents and 167 offspring, analysing the relationship between two variants (Glu298Asp and intron 4) of eNOS gene with ambulatory blood pressure and left ventricular mass, no association was found between the polymorphisms and left ventricular mass index [7].

Works from 90s demonstrated that alpha-adrenergic receptors (ADRA) polymorphisms could be important for blood pressure regulation in specific ethnic populations by mechanisms such as salt excretion, platelet aggregation and baroreceptor sensitivity [8,9]. Freitas and colleagues studied the association between the Arg347Cys polymorphism in the ADRA1A gene and blood pressure phenotypes, in 1568 Brazilians of Vitória City metropolitan area, and they found that Cys/Cys genotype tended to be associated with diastolic blood pressure increase and hypertension in this population [10]. A meta-analysis showed a significant association between the bradykinin B2 receptor polymorphism −587C/T and essential hypertension in 11 studies including 3382 subjects according to different genetic models [11]. Other meta-analysis that evaluated three well-studied eNOS polymorphisms, including 19284/−786C (rs1799983), 6890/6858 cases/controls for G894T (rs1799983), 6890/6858 cases/controls for 4b/a, and 5346/6392 case controls T, revealed that 894T and 4b alleles in Asians and the −786C allele in Caucasians increase the risk of hypertension. The authors suggested that the influence of eNOS variants on the risk of hypertension may be dependent of an ethnic background [12].

The genetic influence on blood pressure and left ventricular mass responses in individuals without cardiovascular disease is not nearly well established as in patients with hypertension. Additionally, there is evidence that in patients without overt heart disease, some subclinical findings such as borderline high-normal blood pressure and left ventricular mass augmentations may precede clinical cardiovascular disease [13]. Our focus was to evaluate common genetic polymorphisms in important pathways related to the regulation of the cardiovascular system which encompassed variants of the bradykinin B2 receptor, alpha-adrenergic receptors and endothelial nitric oxide synthase (eNOS) genes relative to blood pressure and left ventricular mass in a Brazilian cohort of individuals without overt heart disease. We selected the specific genetic polymorphisms based on their importance and functional effects on cardiovascular function as previously described in the literature.

2. Methods

2.1. Study sample

From a cohort of 1015 volunteers aged 18 years old or more, interested in cardiovascular health examination, enrolled between February 2005 and April 2010, we analyzed data from 758 participants, 414 (54.6%) female and 344 (45.3%) male that had blood samples collected for genetic analysis and had undergone a transthoracic 2D echocardiogram. After informed consent, participants underwent clinical examination, 12-lead electrocardiogram and laboratory work up.

2.2. Exclusion criteria

Participants with previous history or evidence of heart disease during the initial clinical evaluation were excluded from the study. Additionally, patients with a history of diabetes mellitus, cerebrovascular disease, cancer, chronic obstructive pulmonary disease, thyroid disease, or other significant systemic diseases were also excluded.

2.3. Blood pressure measurement

Blood pressure was measured during the first appointment in sitting position using an aneroid sphygmomanometer. The patients were instructed to avoid caffeinated beverages, smoking and emptying their bladders at least 30 min before measurement.

2.4. Left ventricular mass measurement

The left ventricular mass was measured by echocardiography following Dereveux formula: left ventricular mass (g) = 0.8 × 1.04 × \([LV\ diastolic\ diameter + interventricular septum + posterior wall thickness]^3 – LV\ diastolic\ diameter^3\] + 0.6 [14].

2.5. Genotyping

Genomic DNA from subjects was extracted from a peripheral blood following standard salting-out procedure. Genotypes for the polymorphisms ADRA1A rs1048101 (Arg347Cys), ADRA2A rs553668 (1780 C>T), ADRA2B rs28365031 (Del 301–303), eNOS rs2070744 T786C (−786 T>C), eNOS rs1799993 (Glu298Asp), and BDKRB2 rs5810761 (Table 1) were detected by polymerase chain reaction (PCR) followed by high-resolution melting analysis with the Rotor Gene 6000® instrument (Qiagen, Courtaboeuf, France). The QiAgility® (Qiagen, Courtaboeuf, France), an automated instrument, was used according to manufacturer’s instructions to optimize the sampling preparation step. One specific disc is able to genotype 96 samples for these polymorphisms.

Amplification of the fragment was performed using the primers for the polymorphisms studied a PCR with 4 cycles. PCR was carried out with the following conditions: denaturation of the template DNA for first cycle of 94 °C for 120 s, denaturation of 94 °C for 20 s, annealing of 53.4 °C for 20 s and extension of 72 °C for 22 s. PCR was performed using a 10 μL reaction solution (10 mM Tris–HCl, 50 mM KCl, pH 9.0; 2.0 mM MgCl2; 200 μM of each dNTP; 0.5 U Taq DNA polymerase; 200 nM of each primer; 10 ng of genomic DNA template) with addition of fluorescent DNA-intercalating SYTO9 (0.15 μM); Invitrogen, Carlsbad, USA). In the HRM phase, the Rotor Gene 6000 measured the fluorescence at each 0.1 °C temperature increase in the range of 73–85 °C.

| Table 1 Study genetic polymorphisms. |
| --- | --- | --- | --- | --- |
| Gene | Genetic polymorphism | Genotype | NCBI register | Type |
| ADRA1A | Arg347Cys | TT, CT, CC | rs1048101 | Coding region |
| ADRA2A | 1780 C>T | TT, CT, CC | rs553668 | 3’UTR |
| ADRA2B | Del 301–303 | II, ID, DD | rs28365031 | Coding region |
| eNOS | −786T>C | TT, TC, CC | rs2070744 | Promoter region |
| BDKRB2 | Glu298Asp | GG, GT, TT | rs1799993 | Coding region |
| Type II Bradykinin receptor | Type II Bradykinin receptor | | | Coding region |

NCBI, National Center of Biotechnology Information; ADRA1A, alpha-adrenergic receptor 1A; ADRA2A, alpha-adrenergic receptor 2A; ADRA2B, alpha-adrenergic receptor 2B; eNOS, endothelial nitric oxide synthase.
Melting curves were generated by the decrease in fluorescence with the increase in the temperature; and in analysis, nucleotide changes resulted in three different curve patterns. Samples of the three observed curves were analysed using bidirectional sequencing as a validation procedure (ABI Terminator Sequencing Kit and ABI 3500XL Sequencer—Applied Biosystems, Foster City, California, USA). The two methods gave identical results in all tests. The wild-type, heterozygous and mutant homozygous genotypes were easily discernible by HRM analysis. In addition, 4% of the samples were randomly selected and reanalysed as quality controls, and gave identical results [15].

3. Demographic and laboratory data

Weight and height were measured, and body mass index (BMI) was calculated. Ethnicity was classified for the Brazilian population according to a set of phenotypic characteristics (such as skin color, hair texture, shape of the nose, and aspect of the lips) and individuals were classified as white, mixed, black and other ethnic groups. The participants were classified as current smokers or non-smokers.

Laboratory workup included fasting plasma glucose, cholesterol and lipoproteins, serum triglycerides, serum creatinine, hemoglobin, leukocyte count, thyroid test and high-sensitivity C-reactive protein.

3.1. Statistical analysis

Continuous data are expressed as mean ± standard deviation. Categorical data are expressed as number and percentage. The Hardy-Weinberg proportions for each polymorphism studied were determined using the chi-square test. The correlation coefficients between continuous variables were performed with Pearson’s correlation test. Student’s t-test and Mann-Whitney U test (when appropriate) were performed for comparison of the means between two groups.

Multiple linear regression models were performed to study associations between the study genetic polymorphisms and the response variables systolic blood pressure, diastolic blood pressure and LV mass. The demographic and laboratory covariates included in the models were age, gender, ethnicity, body mass index, smoking status, HDL-cholesterol, total cholesterol and fasting glucose. Analysis of residuals was performed to test whether the requirements of the models were properly met.

3.2. Ethics

The study protocol was approved by the Committee of Ethics on Human Research of the Hospital and all participants were instructed about the study and signed an informed consent.

4. Results

The clinical characteristics of the study population are shown in Table 2. In relation to ethnicity, 502 (66.2%) participants were White, 101 (13.3%) participants were Mixed, 36 (4.8%) participants were Black, 11 (1.4%) participants were from other ethnic groups and in 108 (14.3%) had no report and ethnicity was not retrieved; 145 (19.1%) participants reported to be active smokers. 108 (14.3%) had no report and ethnicity was not retrieved; 145 (19.1%) participants reported to be active smokers.

There were weak correlations between LV mass and systolic blood pressure (r = 0.22) and diastolic blood pressure (r = 0.21).

In relation to the genetic distributions, all genetic polymorphisms were in Hardy-Weinberg equilibrium, except for the ADRA2B rs28365031 polymorphism (p < 0.001).

4.1. Blood pressure, LV mass and genetic associations

The predictor variables included in the final regression model relative to systolic and diastolic blood pressures are shown in Table 3. The BDKRB2 rs5810761 polymorphism was associated with blood pressure. Carriers of DD genotype had higher levels of SBP and DBP than carriers of II genotype (p = 0.013 and p = 0.001, respectively). The eNOS rs1799983 polymorphism was associated with DBP. Carriers of GT genotype had lower levels of SBP and DBP than carriers of GG genotype (p = 0.018).

The predictor variables included in the final regression model relative to left ventricular mass are shown in Table 4. The eNOS rs2070744 polymorphism was associated with LV mass. Carriers of TC genotype had higher LV mass than carriers of TT genotype (p = 0.028).

In the multivariate analysis, genetic polymorphisms of alpha-adrenergic receptors were not associated with blood pressure or LV mass phenotypes.

Table 3

| Variable                | Estimate | p-Value |
|-------------------------|----------|---------|
| Systolic blood pressure |          |         |
| Blood glucose           | −5.24    | −0.001  |
| eNOS rs1799983 (GT)     | 6.3716   | 0.06    |
| eNOS rs1799983 (TT)     | 9.9154   | 0.08    |
| BDKRB rs5810761 (Ins/Ins)** | 4.2216 | 0.21    |
| BDKRB rs5810761 (Del/Del)** | 8.8710 | 0.013   |
| eNOS rs2070744 (TC)**   | 0.4523   | 0.82    |
| eNOS rs2070744 (CC)**   | −1.9654  | 0.53    |
| Diastolic blood pressure|          |         |
| BMI > 30 kg/m²           | 3.80     | −0.001  |
| Male gender             | 1.98     | 0.01    |
| eNOS rs1799983 (GT)     | −5.2767  | 0.011291|
| eNOS rs1799983 (TT)     | −1.4691  | 0.061497|
| BDKRB rs5810761 (Ins/Ins)** | 2.9604 | 0.164208|
| BDKRB rs5810761 (Del/Del)** | 6.7474 | 0.006561|

BMI, body mass index; BDKRB, bradykinin B2-receptor; eNOS, endothelial nitric oxide synthase.
* Considering GG genotype as reference.
** Considering II genotype as reference.
*** Considering TT genotype as reference.

Table 4

| Variable                | Estimate | p-value |
|-------------------------|----------|---------|
| Systolic blood pressure |          |         |
| Male gender             | 41.98    | <0.001  |
| BMI > 30 kg/m²           | 24.96    | <0.001  |
| BMI 25–30 kg/m²          | 8.72     | <0.001  |
| ADR1A rs1048101 (Arg/Cys) | −0.75 | 0.82    |
| ADR1A rs1048101 (Cys/Cys) | −0.10 | 0.98    |
| eNOS rs2070744 (TC)     | 5.31     | 0.027   |
| eNOS rs2070744 (CC)     | 4.10     | 0.28    |

BMI, body mass index; eNOS, endothelial nitric oxide synthase.
* Considering Arg/Arg genotype as reference.
** Considering TT genotype as reference.

Table 2

| Variable                | Mean (SD) |
|-------------------------|-----------|
| Age                     | 43.1 (13.2)|
| Body mass index (Kg/m²) | 26.3 (4.4)|
| Systolic blood pressure (mm Hg) | 124.1 (13.5)|
| Diastolic blood pressure (mm Hg) | 80.9 (9.2)|
| Creatinine (mg/dL)      | 0.84 (0.17)|
| Glucose (mg/dL)         | 92.4 (8.6)|
| Total cholesterol (mg/dL) | 193.5 (38)|
| HDL cholesterol (mg/dL) | 49.1 (13.5)|
| LDL cholesterol (mg/dL) | 121.4 (32.6)|
| Triglyceride (mg/dL)    | 117.6 (77.4)|
| Left ventricular mass (g) | 1583 (40.9)|

SD, standard deviation.
5. Discussion

In the present study of individuals without overt heart disease, we found significant associations of two functional eNOS genetic polymorphisms with diastolic blood pressure and LV mass as well as a significant association between BDKRB2 rs5810761 polymorphism and both diastolic and systolic blood pressure, even after controlling covariates related to these phenotypes such as age, gender, body mass index, smoking status and metabolic characteristics.

With respect to genetic associations, we observed the BDKRB2 rs5810761 variant significantly influencing the levels of systolic and diastolic blood pressure. It is believed that bradykinin receptors contribute to blood pressure regulation and their inhibition are related to attenuated blood pressure response to angiotensin-converting enzyme inhibition [16,17]. In a British study with 2706 apparently healthy men, 2 functional variants of the bradykinin type I and type II receptors, including the BDKR2 deletion polymorphism, were strongly associated with hypertension and with coronary events [18]. Our study is in line with another Brazilian population-based study from Vitória city with 1570 participants that showed the deletion allele of BDKRB2 rs5810761 polymorphism was associated with higher levels of diastolic blood pressure and with the risk of hypertension [19]. In a sample of 166 normotensive white Americans the same polymorphism was associated with systolic blood pressure, but homozygous carriers of deletion allele had lower levels than carriers of the insertion allele [20]. These evidences suggest genetic variants of bradykinin type II receptor gene may participate in blood pressure regulation, but this contribution may suffer influences from geographic differences.

The nitric oxide (NO) molecule is involved with the regulation of blood pressure, principally due its vasodilator effect on the peripheral resistance vasculature, and the eNOS activity is important to this process [21]. Previous studies have evaluated the impact of eNOS polymorphisms on blood pressure in different populations. These data have been controversial and also appear to be in accordance with another Brazilian population-based study from Vitória city with 1570 participants that showed the deletion allele of BDKRB2 rs5810761 polymorphism was associated with higher levels of diastolic blood pressure and with the risk of hypertension [19]. In a sample of 166 normotensive white Americans the same polymorphism was associated with systolic blood pressure, but homozygous carriers of deletion allele had lower levels than carriers of the insertion allele [20]. These evidences suggest genetic variants of bradykinin type II receptor gene may participate in blood pressure regulation, but this contribution may suffer influences from geographic differences.

The nitric oxide (NO) molecule is involved with the regulation of blood pressure, principally due its vasodilator effect on the peripheral resistance vasculature, and the eNOS activity is important to this process [21]. Previous studies have evaluated the impact of eNOS polymorphisms on blood pressure in different populations. These data have been controversial and also appear to be in accordance with another Brazilian population-based study from Vitória city with 1570 participants that showed the deletion allele of BDKRB2 rs5810761 polymorphism was associated with higher levels of diastolic blood pressure and with the risk of hypertension [19]. In a sample of 166 normotensive white Americans the same polymorphism was associated with systolic blood pressure, but homozygous carriers of deletion allele had lower levels than carriers of the insertion allele [20]. These evidences suggest genetic variants of bradykinin type II receptor gene may participate in blood pressure regulation, but this contribution may suffer influences from geographic differences.

The nitric oxide (NO) molecule is involved with the regulation of blood pressure, principally due its vasodilator effect on the peripheral resistance vasculature, and the eNOS activity is important to this process [21]. Previous studies have evaluated the impact of eNOS polymorphisms on blood pressure in different populations. These data have been controversial and also appear to be in accordance with another Brazilian population-based study from Vitória city with 1570 participants that showed the deletion allele of BDKRB2 rs5810761 polymorphism was associated with higher levels of diastolic blood pressure and with the risk of hypertension [19]. In a sample of 166 normotensive white Americans the same polymorphism was associated with systolic blood pressure, but homozygous carriers of deletion allele had lower levels than carriers of the insertion allele [20]. These evidences suggest genetic variants of bradykinin type II receptor gene may participate in blood pressure regulation, but this contribution may suffer influences from geographic differences.

In a cohort of individuals without overt heart disease, the BDKRB2 rs5810761 polymorphism (DD genotype carriers) were associated with higher systolic and diastolic blood pressures, and the eNOS rs1799983 polymorphism (T allele carriers) were associated with lower diastolic blood pressure. The eNOS rs2070744 polymorphism (C allele carriers) was associated with higher left ventricular mass. These data suggest that eNOS and bradykinin receptor genetic variants may be potential markers of common cardiovascular phenotypes.

6. Conclusions

In a cohort of individuals without overt heart disease, the BDKRB2 rs5810761 polymorphism (DD genotype carriers) were associated with higher systolic and diastolic blood pressures, and the eNOS rs1799983 polymorphism (T allele carriers) were associated with lower diastolic blood pressure. The eNOS rs2070744 polymorphism (C allele carriers) was associated with higher left ventricular mass. These data suggest that eNOS and bradykinin receptor genetic variants may be potential markers of common cardiovascular phenotypes.

Acknowledgements

We thank Amanda A. Holanda and André C. Perette for their support to the statistical analysis.

Funding source

This study was supported in part by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) grants number 2009/52992-1 and 2014/15228-0.

Statement of competing interests

The authors report no competing interests.

References

[1] S. Chopra, C. Baby, J.J. Jacob, Neuro-endocrine regulation of blood pressure, Indian J. Endocrinol. Metab. 15 (2011) S281–S288.
[2] H. Schunkert, H.W. Hense, S.R. Holmer, M. Stender, S. Perz, U. Keil, B.H. Lorell, G.A. Riegger, Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy, N. Engl. J. Med. 330 (23) (1994) 1634–1638.
[3] J.R. Jeng, Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension, Am. J. Hypertens. 12 (5) (1999) 443–450.
[4] P. Hallberg, L. Lind, K. Michaëlsson, J. Karlsson, L. Kurland, T. Kahan, M. Malmqvist, P. Olofman, F. Nyström, Melhus H.B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish ibersartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial, J. Hypertens. 21 (3) (2003) 621–624.
[5] Y. Fu, T. Katsuya, A. Matsuo, K. Yamamoto, H. Akasaka, Y. Takami, Y. Iwashima, K. Sugimoto, K. Ishikawa, M. Ohishi, H. Rakugi, T. Ogihara, Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy, Hypertens. Res. 27 (12) (2004) 933–938.
[6] J. Karvonen, H. Kauma, K. Kervinen, M. Rantalä, M. Ilkäheimo, M. Päivänsalo, M.J. Savolainen, Y.A. Kesäniemi, Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort, J. Intern. Med. 251 (2002) 102–110 (University of Oulu, Oulu, Finland).
[7] D. Czarnecka, K. Kawecka-Jaszc, K. Stolarz, A. Olszanecka, A. Dembińska-Kiec, B. Kiec-Wilk, Ambulatory blood pressure, left ventricular mass and vascular
phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study, J. Hum. Hypertens. 19 (5) (2005) 413–420.

[8] K. Freeman, S. Farrow, A. Schmaier, R. Freedman, T. Schork, W. Lockette, Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans, Am. J. Hypertens. 8 (1995) 863–869.

[9] W. Lockette, S. Ghosh, S. Farrow, S. MacKenzie, S. Baker, P. Miles, A. Schork, L. Cadaret, Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks, Am. J. Hypertens. 8 (1995) 390–394.

[10] S.R. Freitas, A.C. Pereira, M.S. Floriano, J.G. Mill, J.E. Krieger, Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population, BMC Cardiovasc. Disord. 8 (Dec 23 2008).

[11] Yan-yan Li, Hui Zhang, Jian Xu, Yun Qian, Xin-zheng Lu, Bing Yang, M.M. Pretorius, J.V. Gainer, G.P. Van Guilder, et al., The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance, Clin. Pharmacol. Ther. 83 (2008) 122–129.

[12] M. Hermann, A. Flammer, T.F. Lüscher, Nitric oxide in hypertension, J. Clin. Hypertens. (Greenwich) 8 (12 Suppl. 4) (2006) 17–29.

[13] B. Wolff, H.J. Gabe, C. Schützer, et al., Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample, J. Hypertens. 23 (2005) 1361–1366.

[14] K. Srivastava, R. Narang, V. Sreenivas, Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians, Clin. Chim. Acta 387 (2008) 80–83.

[15] W. Tang, Y. Yang, B. Wang, Association between a G894T polymorphism of eNOS gene and essential hypertension in Hani and Yi minority groups of China, Arch. Med. Res. 39 (2008) 222–225.

[16] Y. Miyamoto, Y. Saito, M. Nakayama, et al., Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a −786T → C mutation associated with coronary spastic angina, Hum. Mol. Genet. 9 (2000) 2629–2637.

[17] G.P. Rossi, S. Taddei, A. Virdis, et al., The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients, J. Am. Coll. Cardiol. 41 (2003) 938–945.

[18] H. Zhu, X. Wang, Y. Dong, F.A. Treiber, H. Snedder, Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multietnic youth, Pharmacogenet. Genomics 15 (2005) 669–675.

[19] Y. Xin, X. Song, H. Xue, Z. Liu, X. Wang, H. Wang, K. Sun, Y. Bai, A common variant of the eNOS gene (E298D) is an independent risk factor for left ventricular hypertrophy in human essential hypertension, Clin. Sci. (Lond.) 117 (2009) 675–680.

[20] T.C. Lins, R.G. Vieira, B.S. Abreu, D. Grattapaglia, R.W. Pereira, Genetic composition of Three Well-Characterized Polymorphisms with Hypertension, PLoS One 6 (9) (2011), e24266.

[21] K. Srivastava, R. Narang, V. Sreenivas, Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians, Clin. Chim. Acta 387 (2008) 80–83.

[22] W. Tang, Y. Yang, B. Wang, Association between a G894T polymorphism of eNOS gene and essential hypertension in Hani and Yi minority groups of China, Arch. Med. Res. 39 (2008) 222–225.

[23] Y. Miyamoto, Y. Saito, M. Nakayama, et al., Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a −786T → C mutation associated with coronary spastic angina, Hum. Mol. Genet. 9 (2000) 2629–2637.

[24] G.P. Rossi, S. Taddei, A. Virdis, et al., The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients, J. Am. Coll. Cardiol. 41 (2003) 938–945.

[25] H. Zhu, X. Wang, Y. Dong, F.A. Treiber, H. Snedder, Influence of the eNOS gene on development of blood pressure and left ventricular mass: longitudinal findings in multietnic youth, Pharmacogenet. Genomics 15 (2005) 669–675.

[26] Y. Xin, X. Song, H. Xue, Z. Liu, X. Wang, H. Wang, K. Sun, Y. Bai, A common variant of the eNOS gene (E298D) is an independent risk factor for left ventricular hypertrophy in human essential hypertension, Clin. Sci. (Lond.) 117 (2009) 675–680.

[27] T.C. Lins, R.G. Vieira, B.S. Abreu, D. Grattapaglia, R.W. Pereira, Genetic composition of Three Well-Characterized Polymorphisms with Hypertension, PLoS One 6 (9) (2011), e24266.